P. Garnero et al., Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study, J BONE MIN, 15(8), 2000, pp. 1526-1536
The mechanisms leading to increased bone loss and skeletal fragility in wom
en with postmenopausal osteoporosis are still poorly understood. Increased
bone resorption, low serum estradiol and high serum sex-hormone-binding glo
bulin (SHBG) recently have been reported as predictors of vertebral and hip
fractures in elderly women. In a cohort of healthy untreated younger postm
enopausal women aged 50-89 years (mean, 64 years), we compared baseline lev
els of bone markers and endogenous hormones in 55 women who subsequently ha
d a fracture (20 vertebral and 35 peripheral fractures) with levels in the
380 women who did not fracture during a mean 5 years of follow-up. Women wi
th levels in the highest quartile of four bone resorption markers including
urinary-free deoxypyridinoline (D-Pyr), urinary type I collagen N-telopept
ides (NTX), and urinary and serum type I collagen C-telopeptides (CTX) had
about a a-fold increased risk of fractures compared with women with levels
in the three lowest quartiles with relative risk (RR) and 95% CI of 1.8 (1.
0-3.4) for free D-Pyr, 1.7 (0.9-3.2) for urinary NTX, 2.3 (1.3-4.1) for uri
nary CTX, and 2.1 (1.2-3.8) for serum CTX. Serum levels of bone alkaline ph
osphatase (BAP) in the highest quartile were associated with an RR of fract
ure of 2.4 (1.3-4.2). Women with serum levels of estradiol and dehydroepian
drosterone (DHEA) sulfate in the lowest quartile had an RR of fracture of 2
.2 (1.2-4.0) and 2.1 (1.2-3.8), respectively. Increased levels of SHBG and
intact parathyroid hormone (PTH) were moderately associated with an increas
ed risk of fracture. Similar results were obtained when the analysis was re
stricted to symptomatic vertebral and nonvertebral fractures. Adjustment of
biochemical markers by hormone levels did not significantly alter the resu
lts. Women with both high bone resorption markers and low estradiol (or low
DHEA sulfate) had a higher risk of fracture with RRs of 3.0-3.3 (p < 0.001
). After adjustment for bone mineral density (BMD) of the hip, spine, radiu
s, or total body, bone markers and hormones were still predictive of fractu
re risk with similar RRs. We conclude that high levels of some biochemical
markers of bone turnover, low serum estradiol, low DHEA sulfate, high SHBG,
and high PTH are associated with increased risk of osteoporotic fracture i
n postmenopausal women, independently of each other and of BMD. The mechani
sm by which some postmenopausal women have an increased rate of bone turnov
er leading to an increased risk of fracture remains to be elucidated.